XSPRAY.ST

Xspray Pharma AB (publ) [XSPRAY.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XSPRAY.ST Stock Summary

Top 10 Correlated ETFs

XSPRAY.ST

Top 10 Correlated Stocks

XSPRAY.ST

In the News

XSPRAY.ST Financial details

Company Rating
-
Market Cap
1.27B
Income
-179.11M
Revenue
29.2M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-5.22
Forward P/E
-
PEG
-2.96
P/S
-
P/B
1.42
P/C
-
P/FCF
-4.12
Quick Ratio
3.94
Current Ratio
4.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.21
EPS next Y
-
EPS next Q
-
EPS this Y
10.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
16.35%
-
-
-
-
SMA20
18.99%
SMA50
5.73%
SMA100
-17.23%
Inst Own
-
Inst Trans
-
ROA
-26%
ROE
-33%
ROC
-0.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
28.1-71.94398
52W High
-50.99%
52W Low
+24.29%
RSI
57.28
Rel Volume
0.71
Avg Volume
16.59K
Volume
11.75K
Perf Week
-2.25%
Perf Month
16.19%
Perf Quarter
-41.21%
Perf Half Y
-40.81%
-
-
-
-
Beta
0.84
-
-
Volatility
1.68%, 3.02%
Prev Close
4.98%
Price
34.8
Change
3.73%

Something similar

Top by Market Cap
AMZN
1YD.DE
BRK-A
META
VOO
Top Correlated ETFs
TCBT.DE
JREB.DE
EUNR.DE
UIMC.DE
SUOG.L
Top Correlated Stocks
OV8.SI
TTEN3.SA
TEND3.SA
DNLM.L
INSE.L
Similar Market Cap
600721.SS
603937.SS
BASE
KAR
COWN

Company Profile

Healthcare Biotechnology
  • Volume Average 16.59K
  • Market Capitalization 1.27B
  • Employee 26
  • CEO Dr. Per Andersson Ph.D.
  • Headquarters Solna,SE
  • IPO Date 2017-09-28
  • Website https://www.xspraypharma.com

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.